From 2018 until her retirement in 2023, Dr. Dunsire served as CEO of H. Lundbeck A/S, a global biopharmaceutical company focused exclusively on neurological and psychiatric diseases. She previously served as president, CEO and a director of XTuit Pharmaceuticals, Inc., a private biopharmaceutical company, and president, CEO and a director of FORUM Pharmaceuticals. She worked for Takeda Pharmaceutical Company Limited as a corporate officer and director and she served as president, CEO and a director of Millennium Pharmaceuticals, Inc. Prior to Millennium, Dr. Dunsire held various roles of increasing responsibility at Novartis Pharma AG. She currently serves as a director of Syros Pharmaceuticals and Ultragenyx. She was named one of the “10 Women CEOs Leading the Charge” by BioSpace and “Woman of the Year” by the Healthcare Businesswomen’s Association.  She earned her MBBCh from the University of the Witwatersrand in South Africa.